[HTML][HTML] Anticoagulants: a review of the pharmacology, dosing, and complications
M Alquwaizani, L Buckley, C Adams… - Current emergency and …, 2013 - Springer
Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis.
Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have …
Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have …
Treatment of cancer-associated thrombosis
AYY Lee, EA Peterson - Blood, The Journal of the American …, 2013 - ashpublications.org
Therapeutic options for the management of venous thromboembolism (VTE) in patients with
cancer remain very limited. Although low-molecular-weight heparin monotherapy has been …
cancer remain very limited. Although low-molecular-weight heparin monotherapy has been …
Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis
Background Current clinical practice guidelines all recommend the use of therapeutic doses
of low molecular weight heparins (LMWH) for the initial and long-term treatment of cancer …
of low molecular weight heparins (LMWH) for the initial and long-term treatment of cancer …
Pulmonary embolism: risk assessment and management
S Konstantinides, SZ Goldhaber - European heart journal, 2012 - academic.oup.com
Acute pulmonary embolism (PE) poses a significant burden on health and survival. Its
severity ranges from asymptomatic, incidentally discovered subsegmental thrombi to …
severity ranges from asymptomatic, incidentally discovered subsegmental thrombi to …
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review
SS Adam, JR McDuffie, TL Ortel… - Annals of internal …, 2012 - acpjournals.org
Background: New oral anticoagulants (NOACs), including direct thrombin inhibitors (DTIs)
and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of …
and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of …
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double …
GE Raskob, N van Es, A Segers… - The Lancet …, 2016 - thelancet.com
Background Venous thromboembolism occurs commonly in patients with cancer. Direct oral
anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous …
anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous …
[图书][B] Lippincott manual of nursing practice
SM Nettina, ABC Msn, SM Nettina - 2013 - books.google.com
A classic text since it was first published in 1974, the Lippincott Manual for Nursing Practice
(LMNP) has provided essential nursing knowledge and up-to-date information on patient …
(LMNP) has provided essential nursing knowledge and up-to-date information on patient …
[HTML][HTML] Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta‐analysis
MAT Elsebaie, N van Es, A Langston, HR Büller… - Journal of Thrombosis …, 2019 - Elsevier
Essentials• We investigated direct oral anticoagulant (DOAC) use in venous
thromboembolism and thrombophilia.• A comprehensive search identified 10 studies, 8 of …
thromboembolism and thrombophilia.• A comprehensive search identified 10 studies, 8 of …
Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data
GK Dawwas, CE Leonard, JD Lewis… - Annals of internal …, 2022 - acpjournals.org
Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the
treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons …
treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons …
The effect of food on the absorption and pharmacokinetics of rivaroxaban.
J Stampfuss, D Kubitza, M Becka… - International journal of …, 2013 - europepmc.org
Objective Doses of 10 mg, 15 mg, and 20 mg of rivaroxaban are approved for the treatment
and prevention of thromboembolic disorders in adult patients. In six Phase I studies, the …
and prevention of thromboembolic disorders in adult patients. In six Phase I studies, the …